Patents by Inventor Paula Grammas

Paula Grammas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF DIRECT THROMBIN INHIBITORS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20230158006
    Abstract: The present invention relates to the treatment of neurodegenerative diseases by administering an endothelial interrupter. More specifically, the endothelial interrupter is a direct thrombin inhibitor.
    Type: Application
    Filed: April 15, 2021
    Publication date: May 25, 2023
    Inventor: Paula Grammas
  • Use of Endothelial Interrupters in the Treatment of Neurodegenerative Diseases
    Publication number: 20100099731
    Abstract: In various embodiments, the present invention relates generally to methods of treating at least one neurodegenerative disease by administering a medicament comprising an endothelial interrupter.
    Type: Application
    Filed: September 30, 2009
    Publication date: April 22, 2010
    Applicant: Texas Tech University System
    Inventors: Paula Grammas, Randolph B. Schiffer
  • POLYCYCLIC COMPOUNDS FOR USE IN TREATING OCULAR NEURODEGENERATIVE DISEASES
    Publication number: 20090143457
    Abstract: Described herein are various compounds for treatment of ocular neurodegenerative diseases, including but not limited to glaucoma and diabetic retinopathy. The compounds described herein can act to attenuate and/or block calcium release from external neuronal environments as well as intracellular stores.
    Type: Application
    Filed: December 4, 2008
    Publication date: June 4, 2009
    Applicant: NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE
    Inventors: Cornelis J. Van der Schyf, Randolph B. Schiffer, Paula Grammas, Masao Roy Wilson, Werner J. Geldenhuys, Lois-May Bezuidenhout
  • Endothelial-derived toxic factor
    Publication number: 20010012506
    Abstract: A heat-labile, trypsin-sensitive protein of MW 10-50 kDa which is produced by microvessels from patients suffering from Alzheimer's disease or which is derived from mammalian vascular endothelial cells treated to inhibit protein kinase C. The protein is specifically toxic to neuronal cells and is called endothelial-derived toxic factor (EDTF). EDTF acts by inducing necrosis or apoptosis of neuronal cells. Hybridomas which secrete monoclonal antibodies have been raised against EDTF. The antibodies can be used in therapies or in diagnostic assays to detect the presence of EDTF in a body fluid. EDTF can be used in screening assays to identify compounds which inhibit synthesis or activity of EDTF.
    Type: Application
    Filed: December 8, 2000
    Publication date: August 9, 2001
    Inventors: Paula Grammas, Paul H. Weigel
  • Endothelial-derived toxic factor
    Publication number: 20010009764
    Abstract: A heat-labile, trypsin-sensitive protein of MW 10-50 kDa which is produced by microvessels from patients suffering from Alzheimer's disease or which is derived from mammalian vascular endothelial cells treated to inhibit protein kinase C. The protein is specifically toxic to neuronal cells and is called endothelial-derived toxic factor (EDTF). EDTF acts by inducing necrosis or apoptosis of neuronal cells. Hybridomas which secrete monoclonal antibodies have been raised against EDTF. The antibodies can be used in therapies or in diagnostic assays to detect the presence of EDTF in a body fluid. EDTF can be used in screening assays to identify compounds which inhibit synthesis or activity of EDTF.
    Type: Application
    Filed: December 8, 2000
    Publication date: July 26, 2001
    Inventors: Paula Grammas, Paul H. Weigel